Formosa Pharmaceuticals, Inc. (TPE:6838)

Formosa Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	264.73	425.79	384.71	267.34	208.92	41.87
Short-Term Investments	1,330	1,220	831.41	153.55	-	-
Cash & Short-Term Investments	1,595	1,646	1,216	420.89	208.92	41.87
Cash Growth	35.71%	35.33%	188.94%	101.46%	398.99%	-49.77%
Other Receivables	55.08	51.66	46.44	14.72	13.88	10.21
Receivables	55.38	51.66	46.44	14.72	13.88	10.21
Inventory	1.92	2.89	-	-	-	-
Prepaid Expenses	28.22	26.94	25.34	20.57	11.66	0.69
Other Current Assets	1.33	0.52	0.44	0.13	0.04	1.76
Total Current Assets	1,682	1,728	1,288	456.31	234.5	54.52
Property, Plant & Equipment	37.27	29.89	34.36	10.18	8.19	14.11
Long-Term Investments	0.5	5.15	27.26	-	-	-
Goodwill	30.54	30.54	30.54	30.54	30.54	30.54
Other Intangible Assets	302.75	311.85	345.64	380.2	414.83	362.02
Other Long-Term Assets	7.05	7.05	0.65	0.67	0.65	0.65
Total Assets	2,060	2,112	1,727	877.91	688.72	461.85
Accrued Expenses	109.1	128.36	86.67	66.09	7.17	3.2
Current Portion of Leases	5.05	5.5	5.5	2.5	2.76	3.03
Current Unearned Revenue	25.1	4.51	71.33	-	-	-
Other Current Liabilities	61.26	59.59	94.48	0.98	9.37	39.64
Total Current Liabilities	200.51	197.95	257.98	69.57	19.3	45.88
Long-Term Leases	19.35	20.3	24.29	4.41	0.42	3.18
Long-Term Unearned Revenue	4.21	23.48	1.66	-	-	-
Long-Term Deferred Tax Liabilities	3.83	3.95	4.45	4.94	5.43	5.93
Other Long-Term Liabilities	322.09	318.02	297.84	331.6	270.33	206.95
Total Liabilities	549.98	563.7	586.21	410.51	295.48	261.93
Common Stock	1,510	1,510	1,341	1,136	988.32	728.32
Additional Paid-In Capital	2,279	2,279	1,780	978.52	620.49	270.49
Retained Earnings	-2,194	-2,153	-1,952	-1,630	-1,202	-800.65
Comprehensive Income & Other	-85.93	-87.59	-29.91	-18.14	-14.53	1.23
Total Common Equity	1,509	1,548	1,140	466.83	392.74	199.38
Minority Interest	0.6	0.59	0.54	0.57	0.49	0.53
Shareholders' Equity	1,510	1,549	1,141	467.4	393.23	199.92
Total Liabilities & Equity	2,060	2,112	1,727	877.91	688.72	461.85
Total Debt	24.4	25.8	29.79	6.9	3.18	6.21
Net Cash (Debt)	1,570	1,620	1,186	413.99	205.74	35.66
Net Cash Growth	36.93%	36.55%	186.56%	101.22%	476.99%	-53.79%
Net Cash Per Share	10.83	11.50	9.56	3.94	2.22	0.51
Filing Date Shares Outstanding	150.98	150.98	134.14	113.64	98.83	98.83
Total Common Shares Outstanding	150.98	150.98	134.14	113.64	98.83	98.83
Working Capital	1,481	1,530	1,030	386.75	215.2	8.64
Book Value Per Share	10.00	10.25	8.50	4.11	3.97	2.02
Tangible Book Value	1,176	1,206	763.85	56.09	-52.64	-193.18
Tangible Book Value Per Share	7.79	7.99	5.69	0.49	-0.53	-1.95
Machinery	17.42	8.14	7.38	7.44	7.44	50.45
Construction In Progress	-	-	-	-	-	0.36
Leasehold Improvements	0.7	0.7	0.45	1.54	1.54	1.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.